JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities.
Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).
We designed our EGFR-TRACTr product candidate as a double-masked TRACTr in which the EGFR-binding domain and the T cell-specific binding domain (CD3e) is masked.
In preclinical studies, JANX008 demonstrated potent cleavage dependent anti-tumor activity and was well tolerated in non-human primates, with limited healthy tissue toxicities or CRS. Additionally, JANX008 exhibited enhanced safety and PK properties relative to unmasked TCEs.